CClinicalTrials.gg
Sign In
CompletedNCT01886417HAVUpdated Mar 10, 2015

Auditory Verbal Hallucinations in Schizophrenia

An observational study in Schizophrenia, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-10.

Sponsored by University Hospital, Grenoble · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Auditory verbal hallucinations (AVHs) are speech perceptions in the absence of a relevant external stimulation. Some accounts of AVHs claim that a deficit in inner speech monitoring would cause the verbal thoughts of the patient to be perceived as external voices resulting in AVHs.

In order to examine whether AVHs correspond to self-generated inner speech, the present study aims at collecting speech muscle activity during covert AVHs (without articulation), overt speech and rest. Surface electromyography (sEMG) is used on schizophrenia patients and control subjects to detect any speech muscle activity during AVH.

02

Conditions studied

  • Schizophrenia
03

In context

Hallucinations

132 studies on the registry are indexed under Hallucinations; 36 are open to participants now.

This study's enrollment of 40 is below the median of 70 across 17 observational studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 815 studies on the registry; 205 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

in- and out-patients

Inclusion criteria

Healthy controls:

  • must be more than 18 years and less than 60 years old
  • pre-inclusion medical examination
  • must have signed consent form
  • must be able to read stimuli on a screen

Schizophrenia patients:

  • must be more than 18 years and less than 60 years old
  • pre-inclusion medical examination
  • must have signed consent form
  • must be able to read stimuli on a screen
  • diagnosed with a schizophrenia disorder according to DSM-IV TR (diagnostic and statistical of mental disorders) (PANSS item P3 greater than 4)
  • prior evaluation of the secondary effects of any medication via Barnes and AIMS scales
  • affiliated with the French social security
  • if under guardianship, must have additional consent form signed by guardian

Exclusion criteria

Exclusion Criteria:

Healthy controls:

  • if aged less than 18 years or more than 60 years
  • diagnosed with any psychiatric disorder
  • with any language disorder (aphasia, SLI, dysarthria, stuttering, etc.)
  • with auditory impairment
  • pregnant, parturient, breast-feeding

Schizophrenia patients:

  • if aged less than 18 years or more than 60 years
  • significant secondary effects of antipsychotic medication, measured with the Barnes and AIMS scales
  • with a neurodegenerative disease
  • with any language disorder (aphasia, SLI, dysarthria, stuttering, etc.)
  • with auditory impairment
  • pregnant, parturient, breast-feeding
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Labial EMG activity during auditory verbal hallucination

    Time frame: up to 3 years

07

Study locations

1 site
  • University Hospital of Grenoble
    Grenoble, 38043, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01886417
Lead sponsor
University Hospital, Grenoble
Collaborators
GIPSA-LAB
Responsible party
Sponsor
First posted
Jun 25, 2013
Start date
Oct 2009
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Mar 10, 2015

Study contacts

Thierry BOUGEROL, MD, PHD, HDR
principal investigator · University Hospital of Grenoble, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hallucinations→

Other studies from this sponsor

University Hospital, Grenoble

Start the discussion